4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.
- Three-year commercial contract with SimonMed Imaging
- Immediate deployment of CT:VQ™ and LDAf™ across 170+ US sites
- Partnership to develop reimbursement evidence with payors
- Strengthens 4DMedical’s US commercial footprint post-FDA clearance
- SimonMed’s network spans 10 states with 300+ radiologists
SimonMed Deal Accelerates CT:VQ™ Commercial Rollout
4DMedical (ASX:4DX) has taken a decisive leap into the US outpatient imaging market by signing a three-year agreement with SimonMed Imaging, one of the country’s largest outpatient imaging providers. SimonMed operates over 170 centres across 10 states, supported by more than 300 radiologists, making this contract a substantial commercial endorsement of 4DMedical’s CT:VQ™ and LDAf™ cardiopulmonary analysis technologies.
The deal enables immediate clinical deployment of CT:VQ™ on commercial terms, bypassing the typical evaluation phase. This signals growing confidence in 4DMedical’s technology just months after its FDA clearance, and follows the company’s recent momentum in securing contracts with leading academic medical centres and regulatory approvals across Europe and the UK, including a major pharmaceutical partnership expanded CT:VQ™ adoption.
Integration into SimonMed’s Outpatient Network
SimonMed’s physician-led approach to technology adoption is methodical, prioritising clinical validation before scaling new tools. By integrating 4DMedical’s quantitative functional lung imaging into its existing CT workflows, SimonMed aims to enhance diagnostic precision for pulmonary diseases such as asthma and COPD. The technology extracts functional cardiopulmonary data from standard CT scans without requiring additional contrast agents or nuclear medicine studies, promising earlier disease detection and more personalised patient management.
SimonMed will also collaborate with 4DMedical to develop reimbursement evidence by sharing insurance and claims data, a crucial step for securing public and private payor support. This partnership aligns with 4DMedical’s broader strategy to accelerate reimbursement visibility and commercial uptake in the US market.
Commercial and Clinical Implications
The commercial structure of the deal, based on per-scan pricing and immediate deployment, underscores the operational and clinical value SimonMed sees in CT:VQ™. 4DMedical’s CEO Andreas Fouras highlighted that this agreement strengthens the company’s position as a partner of choice for next-generation CT-based functional imaging in the US, complementing its leadership in academic medical centres and recent inclusion in the S&P/ASX 200 index.
With the US outpatient imaging market representing a vast addressable opportunity, the SimonMed contract could be a bellwether for further scaled commercial agreements. The company’s SaaS delivery model facilitates rapid deployment across large networks, enhancing physician productivity and patient outcomes.
Earlier clinical validation of CT:VQ™ has shown promising results, such as improving lung volume reduction surgery response rates from 46% to 76%, which may underpin growing clinical adoption 4DMedical Study Boosts Lung Surgery.
Bottom Line?
4DMedical’s SimonMed deal marks a pivotal commercial milestone, but long-term revenue hinges on successful reimbursement and broader US adoption.
Questions in the middle?
- How quickly will SimonMed scale CT:VQ™ scans across its 170+ sites?
- What progress will the partnership make in securing payor reimbursement?
- Could this deal catalyse further commercial contracts with other US imaging networks?